Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.

 

There is limited information on peripheral stent thrombosis and involved factors.

This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”.

Stent thrombosis occurred in 26 of the 604 patients (4.3%) at median 6 month follow up post procedure.

Stent thrombosis was more frequent in men and when the lesion originally treated was a chronic total occlusion.

There were no differences in stent thrombosis between drug-coated and bare metal stents (4.4% vs 3.4%; p=0.55) but there were differences between self-expandable covered stents vs. conventional bare metal stents (10.6% vs 3.4%; p=0.02).

Thrombosis was associated to a much higher risk of adverse events over the same treated limb (HR, 4.99; CI 95% 2.31 to 10.77; p<0.001).

Multivariable analysis showed that chronic total occlusion (OR, 3.46; IC 95% 0.98 a 12.20; p=0.05) and in-stent restenosis (OR, 5.30; IC 95%, 1.83 a 15.32; p=0.002) were independently associated with stent thrombosis.

Conclusion
This multicenter registry of peripheral intervention showed that femoropopliteal stent thrombosis is 4.3% and is associated to the treatment of chronic total occlusions and restenosis of previous stents. Thrombosis is strongly associated to adverse events in this lower limb.

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...